Turn Therapeutics Inc. Operating Cash Flow
Turn Therapeutics Inc. (TTRX) reported Operating Cash Flow of -$2.56 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-12
- Turn Therapeutics Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$923.36K.
- Turn Therapeutics Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$1.63M.
- Turn Therapeutics Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$1.18M.
- Turn Therapeutics Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$588.61K.
- Turn Therapeutics Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$2.56M.
- Turn Therapeutics Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$1.36M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$923.36K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$2.56M 10-Q · filed 2026-08-12 | -$3.73M derived: sum of 3 quarters · filed 2026-08-12 | -$4.32M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$1.63M 10-Q · filed 2026-05-11 | -$2.81M derived: sum of 2 quarters · filed 2026-05-11 | -$3.40M derived: sum of 3 quarters · filed 2026-05-11 | -$3.90M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$1.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$1.76M derived: sum of 2 quarters · filed 2026-03-31 | -$2.26M derived: sum of 3 quarters · filed 2026-08-12 | -$2.56M 10-K · filed 2026-03-31 |
| 2025-09-30 | -$588.61K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$1.09M derived: sum of 2 quarters · filed 2026-08-12 | -$1.39M 10-Q · filed 2025-11-13 | -$1.82M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$499.97K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$798.02K 10-Q · filed 2026-08-12 | -$1.23M derived: sum of 3 quarters · filed 2026-08-12 | |
| 2025-03-31 | -$298.06K 10-Q · filed 2026-05-11 | -$728.60K derived: sum of 2 quarters · filed 2026-05-11 | ||
| 2024-12-31 | -$430.55K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$1.36M 10-K · filed 2026-03-31 | ||
| 2024-09-30 | -$930.76K 10-Q · filed 2025-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |